Navigation Links
Alzheimer's Therapeutics Reviewed by NeuroPerspective
Date:9/6/2012

CARDIFF, Calif., Sept. 6, 2012 /PRNewswire/ -- NI Research has released the September issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics. The focus is particularly timely, given the recent release of Phase III results for bapineuzumab and solaneuzumab, which serve as a reminder of how poorly the pharma industry has allocated its resources to date, both in terms of the premature embrace of the amyloid model, and the rush into hugely expensive Phase III programs without obtaining Phase II justification.

This 46-page issue is the largest and most comprehensive issue of NeuroPerspective ever produced, and includes:

1) An overview of the biology of Alzheimer's as it is currently conceptualized, albeit not yet validated.
2) A review of the many therapeutic strategies that have been employed, and that are currently under development.
3) The companies and programs that are in clinical, preclinical, and discovery stage. Over 215 therapeutic programs are covered in this review. They include variations on the secretase theme from Bristol Myers Squibb, EnVivo Pharmaceuticals, and Neurogenetic Pharmaceuticals; innovative approaches to disease progression from Merck/Alectos, Roche/reMYND, and NeuroPhage; and those with clinical data, such as EnVivo, Lundbeck, TauRx, and Prana.  
4) What is and is not clear from the sparse solanezumab results thus far disclosed, which have served as a Rorschach for those looking to have their preconceptions supported. With all due respect to the fever dreams of some Street analysts, these results are not going to be the basis for filing a NDA.
5) A sampling of novel biomarkers in development for AD, aimed at identifying markers for MCI/prodromal AD that will permit early intervention.
6) A spotlight review of AC Immune, one of the leaders in the development of antibodies for both amyloid and tau.
7) The positive results for EnVivo Pharma's EVP-6124, and the potential for alternate mechanistic approaches to effectively address Alzheimer's.

Other topics covered in NP September:
8) Reading between the line regarding Naurex's rapid-acting antidepressant, the most important neuropsychiatric development of the year.
9) 'Elan 1969-2013:' Ramifications of Elan's decision to spin-out Neotope Bioscience.
10) The status of Merck Serono's restructuring and the implications for its CNS programming.
11) News and developments from Cortex Pharmaceuticals, NeuroSearch, and more.

NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective (formerly NeuroInvestment) is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.

A one-year subscription to NeuroPerspective is $2,300. The September issue of NeuroPerspective is available for $400 as a single-issue purchase.

NI Research also publishes NeuroLicensing, the Private CNS Company Review, and has just launched NeuroSynopsis, a monthly four-page summary of the most important highlights from NeuroPerspective. NIR also provides consulting services to the pharma industry.

Further information and online purchasing with immediate delivery are available at http://www.niresearch.com/onlinestore.html


'/>"/>
SOURCE NI Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
2. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
3. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
4. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
5. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
6. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
7. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
8. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
9. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
10. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
11. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 NanoStruck ... (OTCPink: NSKQB) ( Frankfurt : 8NSK) ... Pressemitteilung vom 13. August 2015 die Genehmigung von ... um zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu ... bringen. Davon wurden 157.900.000 Einheiten mit dem ersten ...
(Date:4/27/2016)... ... 2016 , ... PathSensors, Inc., a leading environmental testing company, ... assist PathSensors in expanding the use of the company’s CANARY® technology in the ... for the detection of harmful pathogens, including a number of bacteria, viruses, toxins, ...
(Date:4/27/2016)... 27, 2016 MedDay, a biotechnology company ... the appointment of Catherine Moukheibir as Chairman of its Board ... Jean Jacques Garaud , who contributed to the rapid ... immediately. Catherine started her career in strategy consulting ... London .  She held C-Suite level roles ...
(Date:4/26/2016)... ... 2016 , ... The European Patent Office (EPO) today announced that ... for the European Inventor Award 2016 in the category "Non-European countries." The winners of ... ceremony in Lisbon on June 9th. , The human capacity to walk with fluidity ...
Breaking Biology Technology:
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
(Date:3/10/2016)... --  Unisys Corporation (NYSE: UIS ) today announced ... testing its biometric identity solution at the Otay Mesa border ... identify certain non-U.S. citizens leaving the country. ... determine the efficiency and accuracy of using biometric technologies in ... until May 2016. --> the United States ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
Breaking Biology News(10 mins):